Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-29

Study Completion Date

2028-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many people who receive a kidney transplant develop problems with how their body processes sugar (glucose). This includes conditions like prediabetes and diabetes, which can lead to more health issues, such as heart problems and infections.

One of the main medications used after a kidney transplant, called tacrolimus, can contribute to these sugar problems. Tacrolimus helps protect the new kidney, but it can also harm the cells in the pancreas that produce insulin, a hormone that controls blood sugar. Other factors, such as stress on the body and insulin resistance, can make things worse.

The effect of tacrolimus on blood sugar may depend on how the body processes the drug. Some people break down tacrolimus quickly (fast metabolizers), so they need higher doses to reach the right level in their blood. Others break it down more slowly (slow metabolizers) and require lower doses. Doctors can measure how fast someone metabolizes tacrolimus using aparameter called the concentration-to-dose (C/D) ratio.

This study aims to find out what increases the risk of developing blood sugar problems after a kidney transplant. It will focus on how quickly patients process tacrolimus and whether this affects their risk of developing diabetes. The study will also look at how common these issues are in kidney transplant patients in Poland.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients

NCT03640026

Kidney Failure, Chronic

RECRUITING PHASE4

Hyperglycemia and (Pre)Diabetes in Pediatric Renal and Liver Transplantation.

NCT05464043

Diabetes Mellitus Risk

COMPLETED NA

Functional Genetic Variants Affecting Tacrolimus Trough Levels and Side Effects in Chinese Renal Transplantation.

NCT03083769

Transplantation

COMPLETED

Improving Medication Safety and CVD Risk Factor Control in Kidney Transplant Recipients

NCT02763943

Cardiovascular Diseases Diabetes Mellitus Medication Adherence

COMPLETED NA

Studies of Organ Transplantation in Animals and Man

NCT00156364

Diabetes Mellitus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LCP Tacro (tacrolimus)

Treatment with LCP Tacro will begin on the day of the kidney transplant. If a patient is switching from another form of tacrolimus to LCP Tacro, the transition will be completed no later than day 8, following the standard procedures of the medical institution.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Recipients of a kidney transplant from a living or deceased donor
* Standard immunosuppressive regimen post-kidney transplantation (KTx) including Envarsus®
* LCP Tacrolimus therapy initiated from the day of KTx or conversion from another tacrolimus formulation to LCP Tacrolimus by day 8 at the latest, according to the institution's routine practice
* Informed patient consent to participate in the study

Exclusion Criteria

* Diagnosis of diabetes (type 1 or type 2) treated with diet or glucose-lowering drugs
* Random glycemia/HbA1c levels justifying a diagnosis of diabetes at the time of study enrollment
* Kidney retransplantation
* Recipients of a multi-organ transplant
* Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss
* Use of flozins for renal or cardiac indications
* Chronic use of drugs affecting carbohydrate metabolism, such as glucocorticosteroids

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alicja Dębska-Ślizień, Professor

Role: PRINCIPAL_INVESTIGATOR

Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdansk, Gdansk, Poland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdansk

Gdansk, , Poland

Site Status RECRUITING